Pacific Biosciences of California (PACB) Projected to Post Quarterly Earnings on Thursday

Key Points

• Pacific Biosciences of California (PACB) is expected to report its Q2 2025 earnings on August 7th, with analysts forecasting an EPS of ($0.18) and revenue of $36.35 million.
• The company's stock is currently trading at $1.49, down 3.2%, and it has a market capitalization of $447.12 million.
• Recent analyst ratings show a mix of sentiments, with target prices ranging from $1.25 to $3.00, and an average rating of "Hold".

Pacific Biosciences of California (NASDAQ:PACB - Get Free Report) is anticipated to release its Q2 2025 earnings data after the market closes on Thursday, August 7th. Analysts expect Pacific Biosciences of California to post earnings of ($0.18) per share and revenue of $36.35 million for the quarter.

Pacific Biosciences of California (NASDAQ:PACB - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biotechnology company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.04. Pacific Biosciences of California had a negative return on equity of 52.07% and a negative net margin of 430.93%. The business had revenue of $37.15 million during the quarter, compared to analyst estimates of $36.90 million. During the same quarter last year, the firm posted ($0.26) earnings per share. On average, analysts expect Pacific Biosciences of California to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pacific Biosciences of California Stock Down 3.6%

Shares of NASDAQ:PACB traded down $0.05 during midday trading on Friday, reaching $1.33. The company's stock had a trading volume of 7,362,621 shares, compared to its average volume of 7,092,971. The firm has a 50 day moving average of $1.32 and a 200-day moving average of $1.33. Pacific Biosciences of California has a 12-month low of $0.85 and a 12-month high of $2.72. The firm has a market capitalization of $399.11 million, a P/E ratio of -0.48 and a beta of 2.17. The company has a quick ratio of 5.87, a current ratio of 6.68 and a debt-to-equity ratio of 7.05.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Canaccord Genuity Group reiterated a "buy" rating and issued a $3.00 price target on shares of Pacific Biosciences of California in a research note on Thursday, April 10th. Piper Sandler cut their price target on Pacific Biosciences of California from $2.00 to $1.25 and set a "neutral" rating for the company in a research note on Thursday, May 15th. Stephens restated an "overweight" rating and issued a $1.80 price target on shares of Pacific Biosciences of California in a research report on Thursday, May 15th. Finally, Barclays lowered their target price on shares of Pacific Biosciences of California from $2.00 to $1.50 and set an "equal weight" rating on the stock in a research note on Wednesday, June 25th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $2.06.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.